Human DNase I hyperactive variants
AssigneeGenentech, Inc.
InventorsRobert A. Lazarus, Clark Qun Pan
Life of this patent
Estimating the term…
Abstract
The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
Claims20
A human DNase I hyperactive variant.
A human DNase I hyperactive variant having an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 by the substitution of one amino acid for another at only a single position within the FIG. 1 sequence.
A human DNase I hyperactive variant having an amino acid sequence that differs from the amino acid sequence shown in FIG. 1 by the substitution of one amino acid for another at two or more positions within the FIG. 1 sequence.
An isolated nucleic acid encoding a human DNase I hyperactive variant.
A method for the treatment of a patient having a pulmonary disease or disorder comprising administering to the patient a therapeutically effective amount of a human DNase I hyperactive variant.
The method of claim is wherein the disease or disorder is cystic fibrosis.
A method for the treatment of a patient having systemic lupus erythematosus comprising administering to the patient a therapeutically effective amount of a human DNase I hyperactive variant.
A pharmaceutical composition comprising a human DNase I hyperactive variant and optionally a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.